Feasibility of Using Source-Level Brain Computer Interface for People with Multiple Sclerosis.

This work evaluates the feasibility of using a source level Brain-Computer Interface (BCI) for people with Multiple Sclerosis (MS). Data used was previously collected EEG of eight participants (one participant with MS and seven neurotypical participants) who performed imagined movement of the right and left hand. Equivalent current dipole cluster fitting was used to assess related brain activity at the source level and assessed using dipole location and power spectrum analysis. Dipole clusters were resolved within the motor cortices with some notable spatial difference between the MS and control participants. Neural sources that generate motor imagery originated from similar motor areas in the participant with MS compared to the neurotypical participants. Power spectral analysis indicated a reduced level of alpha power in the participant with MS during imagery tasks compared to neurotypical participants. Power in the beta band may be used to distinguish between left and right imagined movement for users with MS in BCI applications.Clinical Relevance- This paper demonstrates the cortical areas activated during imagined BCI-type tasks in a participant with Multiple Sclerosis (MS), and is a proof of concept for translating BCI research to potential users with MS.

Feasibility of using discrete Brain Computer Interface for people with Multiple Sclerosis.

AIM: Brain-Computer Interfaces (BCIs) hold promise to provide people with partial or complete paralysis, the ability to control assistive technology. This study reports offline classification of imagined and executed movements of the upper and lower limb in one participant with multiple sclerosis and people with no limb function deficits. METHODS: We collected neural signals using electroencephalography (EEG) while participants performed executed and imagined motor tasks as directed by prompts shown on a screen. RESULTS: Participants with no limb function attained >70% decoding accuracy on their best-imagined task compared to rest and on at-least one task comparison. The participant with multiple sclerosis also achieved accuracies within the range of participants with no limb function loss.Clinical Relevance - While only one case study is provided it was promising that the participant with MS was able to achieve comparable classification to that of the seven healthy controls. Further studies are needed to assess whether people suffering from MS may be able to use a BCI to improve their quality of life.

Erratum: Publisher Correction: Rabies-based vaccine induces potent immune responses against Nipah virus.

[This corrects the article DOI: 10.1038/s41541-019-0109-5.].

Rabies-based vaccine induces potent immune responses against Nipah virus.

Nipah Virus (NiV) is a re-emerging zoonotic pathogen in the genus Henipavirus of the Paramyxoviridae family of viruses. NiV is endemic to Bangladesh and Malaysia and is highly fatal to both livestock and humans (human case fatality rate = 74.5%). Currently, there is no approved vaccine against NiV on the market. The goal of this study was to use a recombinant RABV vector expressing NiV glycoprotein (NiV G) to develop a bivalent candidate vaccine against NiV disease and rabies virus (RABV) disease, which is also a significant health burden in the regions where NiV is endemic. The rabies vector is a well-established vaccine strain that lacks neurovirulence and can stably expresses foreign antigens that are immunogenic in various animal models. Mice inoculated intranasally with the live recombinant RABV/NiV vaccine (NIPARAB) showed no signs of disease. To test the immunogenicity of the vaccine candidate, groups of C57BL/6 mice were immunized intramuscularly with a single dose of live vaccine particles or two doses of chemically inactivated viral particles. Both vaccination groups showed NiV G-specific seroconversion, and the inactivated (INAC) vaccine group yielded higher titers of NiV G-specific antibodies. Furthermore, cross-reactivity of NiV G-specific immune sera against Hendra virus (HeV), was confirmed by immunofluorescence (IF) and indirect ELISA against soluble recombinant HeV glycoprotein (HeV G). Both live and killed vaccines induced neutralizing antibodies. These results indicate that NIPARAB may be used as a killed virus vaccine to protect humans against NiV and RABV, and possibly as a preventative measure against HeV as well.